BioNTech faces its biggest post pandemic crisis
Key takeaways
- Bio NTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders.
- https://p.dw.com/p/5DLBEBio NTech was founded in 2008 but gained global attention for its COVID vaccines.
- Today, however, the Mainz-based biotech firm is facing a harsh reckoning.
Why this matters: an international story with cross-border implications worth tracking.
Bio NTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?
https://p.dw.com/p/5DLBEBio NTech was founded in 2008 but gained global attention for its COVID vaccines. Can the biotech pioneer reinvent itself before momentum fades?Image: Andreas Arnold/dpa/picture alliance Advertisement Six years ago, an almost unknown German pharmaceutical firm developed the first approved mRNA COVID-19 vaccine and changed the course of a global pandemic.
BioNTech, which had spent over a decade developing mRNA for cancer with little commercial interest, partnered with Pfizer to roll out its Comirnaty coronavirus vaccine in record time, propelling the company and its founders to global fame.